Enterprise AI Analysis
Functional rescue and AI analysis of a human inactivating GPCR mutation using a small molecule
G protein-coupled receptors (GPCRs) carry out the majority of cellular transmembrane signaling. Many pathologies have underlying GPCR mutations, most of which cause misfolding and GPCR cell surface trafficking failure. Large libraries of existing small molecule GPCR ligands could be repurposed as pharmacological chaperones (PCs) which restore mutant GPCR folding and function, presenting an exciting alternative to complex gene repair, yet such in vivo studies are limited. Therefore, as proof-of-concept, we use one such known ligand/PC, Org42599/Org43553, to show functional rescue in mice bearing an inactivating human luteinizing hormone receptor (LHR) mutation. Mutant males had delayed puberty and Leydig cell LHR signaling impairment, however, fertility was unaffected. Mutant females had irregular estrous cycles, anovulation, abrogated ovarian LHR signaling, and complete infertility. PC treatment of mutant females restored LH signaling and estrous cyclicity. To characterize treatment efficacy, we developed an AI algorithm that reliably identified inherent differences among experimental groups, enabling functional analysis of the treatment effect in vivo. Our data set the stage to integrate AI analysis with GPCR-targeting PC molecules to treat diverse GPCR-based diseases.
Executive Impact: Key Findings at a Glance
Our AI-powered analysis distills complex research into actionable insights, highlighting critical advancements and their potential for enterprise application.
0
GPCRs as Drug Targets
0
LHR-Chap Rescue Efficacy (LH Response)
0
AI Classification Accuracy
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
This category focuses on computational methods and models used to analyze biological data. The paper describes an AI algorithm for classifying cells based on calcium signaling patterns, which is a key computational biology application. This includes the use of t-SNE, K-means clustering, and neural networks to analyze complex biological data and identify inherent differences between experimental groups.
94.21%
AI Model Accuracy in Classifying Ovarian Cells (Hom vs. Het)
Our AI model achieved an impressive 94.21% accuracy in classifying ovarian cells from homozygous mutant (Hom) versus heterozygous control (Het) mice based on their spontaneous calcium profiles, showcasing the power of AI in discerning subtle biological differences. This accuracy indicates the model's high reliability in identifying the functional impact of the LHR mutation even before external stimulation, which is crucial for preclinical diagnostics.
Enterprise Process Flow
LHR-expressing cells isolated from mouse model
→
Calcium imaging data collected (time-series)
→
High-dimensional data (1500 dimensions) represented as vectors
→
AI Model (Neural Network) Training (Het vs. Hom)
→
Feature Space Projection (revealing hidden patterns)
→
Classification of cells based on calcium signatures
The AI pipeline starts with isolating LHR-expressing cells and collecting high-dimensional calcium imaging data. This data is then used to train a feature-learning neural network, optimized for time-series analysis. The network projects the data into a learned feature space, revealing abstract, nonlinear combinations of the original calcium signal that are most informative for distinguishing between Het and Hom groups. This enables reliable classification of cells based on their unique calcium signatures, providing a powerful tool for preclinical diagnosis and drug efficacy assessment.
This category involves the molecular mechanisms underlying diseases. The paper investigates how a specific mutation (T4651) in the LHR GPCR leads to reproductive dysfunction in mice, serving as a model for human diseases caused by GPCR mutations. It explores the molecular basis of misfolding and the rescue by pharmacological chaperones.
| Treatment | Outcome |
|---|---|
| HCG (Control Group) |
|
| LHR-Chap |
|
This comparison highlights the superior therapeutic efficacy of LHR-Chap over HCG in restoring ovarian function in homozygous mutant female mice. While HCG, a conventional ovulation inducer, failed to rectify the reproductive dysfunctions, LHR-Chap successfully regularized estrous cycles, induced ovulation (evidenced by corpora lutea formation), and restored LH-induced calcium signaling. This demonstrates LHR-Chap's potential as a pharmacological chaperone for GPCR-related infertility.
This category relates to the anatomy, physiology, and pathology of the urinary and reproductive organs. The paper specifically addresses the impact of the LHR mutation on male and female reproductive systems, including puberty onset, fertility, estrous cycles, and ovarian function. The rescue of these dysfunctions by LHR-Chap directly impacts the urogenital system.
Fertile
Homozygous Mutant Males Fertility Status
Despite exhibiting reduced body weight and delayed puberty, homozygous mutant males (LhrT465I-IC+/+) surprisingly remained fertile, showing normal breeding patterns and litter characteristics. This suggests a sexual dimorphism in the penetrance of the T465I LHR mutation, where male reproductive function is less severely impacted than female function, potentially due to temperature-dependent protein folding in the testes.
Infertile
Homozygous Mutant Females Fertility Status
In stark contrast to males, homozygous mutant females were completely infertile, showing irregular estrous cycles, absence of ovulation (no corpora lutea), and abrogated ovarian LH signaling. This highlights a profound impact of the LHR T465I mutation on female reproductive health, making them an ideal model for testing pharmacological chaperone rescue strategies.
Estimate Your Enterprise AI Impact
Quantify the potential efficiency gains and cost savings for your organization by integrating AI-powered analysis tools into your research and development workflows. Select your industry and provide key operational metrics to see your projected ROI.
Annual Cost Savings
$0
Research Hours Reclaimed Annually
0
Phased AI Integration Roadmap
Our phased approach ensures a seamless transition and maximum value realization for your AI initiatives. Each phase is designed for clear objectives and measurable outcomes.
Phase 1: Pilot & Data Integration (2-4 Weeks)
Initiate with a focused pilot program. Integrate existing research data (e.g., calcium imaging, genomic profiles) into the AI platform. Establish initial data pipelines and ensure compatibility with current experimental setups. Define success metrics for the pilot phase.
Phase 2: Model Training & Validation (4-8 Weeks)
Train custom AI models using your specific datasets. Validate model performance against historical data and established biological outcomes. Refine algorithms to optimize accuracy and interpretability. Begin generating preliminary insights from the model.
Phase 3: Scaled Deployment & Continuous Learning (8-12 Weeks)
Deploy the validated AI models across your research teams. Implement feedback loops for continuous model improvement. Provide training and support for researchers to maximize adoption. Start leveraging AI for real-time experimental analysis and preclinical decision-making.
Phase 4: Advanced AI Applications & Strategic Expansion (Ongoing)
Explore advanced AI applications, such as predictive modeling for drug efficacy, automated experimental design, and integration with robotic lab systems. Expand AI capabilities to other research areas and therapeutic targets within your enterprise.
Ready to Transform Your Research with AI?
Connect with our experts to explore how these advanced AI analysis techniques can be tailored to your specific enterprise needs and accelerate your scientific breakthroughs.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat